Comparative efficacy of brolucizumab, half-dose photodynamic therapy, and aflibercept in managing chronic central serous chorioretinopathy

被引：0
|
作者：
Yu-Te Huang
Peng-Tai Tien
Po-Yu Chen
Chi-Lan Yang
San-Ni Chen
机构：
[1] China Medical University Hospital,Department of Ophthalmology, Eye Center
[2] China Medical University,School of Medicine, College of Medicine
来源：
Graefe's Archive for Clinical and Experimental Ophthalmology | 2024年 / 262卷
关键词：
Brolucizumab; Half-dose PDT; Aflibercept; Chronic central serous chorioretinopathy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1755 / 1763
页数：8
相关论文
共 50 条
  • [21] Changes in macular sensitivity after half-dose photodynamic therapy for chronic central serous chorioretinopathy
    Atik, Alp
    Hu, Yijun
    Yu, Honghua
    Yang, Chun
    Cai, Bin
    Tao, Yijing
    Li, Dongli
    Chen, Yan
    Lu, Li
    Li, Guodong
    Yuan, Ling
    BMC OPHTHALMOLOGY, 2017, 17
  • [22] Half-dose Versus Half-time Photodynamic Therapy for Central Serous Chorioretinopathy
    Liu, Hsin-Yu
    Yang, Chang-Hao
    Yang, Chung-May
    Ho, Tzyy-Chang
    Lin, Chang-Ping
    Hsieh, Yi-Ting
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2016, 167 : 57 - 64
  • [23] Half-dose photodynamic therapy for chronic central serous chorioretinopathy evaluated by focal macular electroretinograms
    Oiwa, Kazuhiro
    Kataoka, Keiko
    Maruko, Ruka
    Ueno, Shinji
    Ito, Yasuki
    Terasaki, Hiroko
    JAPANESE JOURNAL OF OPHTHALMOLOGY, 2017, 61 (03) : 260 - 266
  • [24] Half-dose photodynamic therapy for chronic central serous chorioretinopathy evaluated by focal macular electroretinograms
    Kazuhiro Oiwa
    Keiko Kataoka
    Ruka Maruko
    Shinji Ueno
    Yasuki Ito
    Hiroko Terasaki
    Japanese Journal of Ophthalmology, 2017, 61 : 260 - 266
  • [25] The safety of fovea-involving half-dose photodynamic therapy for chronic central serous chorioretinopathy
    Feenstra, H. M. A.
    Diederen, R. M. H.
    Lamme, M. J. C. M.
    Fauser, S.
    Downes, S. M.
    Schlingemann, R. O.
    Hoyng, C. B.
    van Dijk, E. H. C.
    Boon, C. J. F.
    ACTA OPHTHALMOLOGICA, 2022, 100 : 19 - 19
  • [26] Changes in macular sensitivity after half-dose photodynamic therapy for chronic central serous chorioretinopathy
    Alp Atik
    Yijun Hu
    Honghua Yu
    Chun Yang
    Bin Cai
    Yijing Tao
    Dongli Li
    Yan Chen
    Li Lu
    Guodong Li
    Ling Yuan
    BMC Ophthalmology, 17
  • [27] Comparison of efficacy, safety and costs between half-fluence and half-dose photodynamic therapy for Chronic Central Serous Chorioretinopathy
    Nicolo, Massimo
    Eandi, Chiara
    Alovisi, Camilla
    Traverso, Carlo
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2013, 54 (15)
  • [28] Photoreceptor disruption in central serous chorioretinopathy treated by half-dose photodynamic therapy
    Ratanasukon, Mansing
    Thongthong, Koblarp
    Bhurayanontachai, Patama
    Jirarattanasopa, Pichai
    CLINICAL OPHTHALMOLOGY, 2013, 7 : 87 - 92
  • [29] Half-Dose Verteporfin Photodynamic Therapy (hdPDT) in the Treatment of Central Serous Chorioretinopathy
    Hoehn, F.
    Kretz, F. T. A.
    Beger, I.
    Koch, F.
    Auffarth, G. U.
    Singh, P.
    Deuchler, S.
    Koss, M. J.
    KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE, 2016, 233 (07) : 860 - 863
  • [30] Comparison of efficacy between low-fluence and half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy
    Alkin, Zeynep
    Perente, Irfan
    Ozkaya, Abdullah
    Alp, Dilek
    Agca, Alper
    Aygit, Ebru Demet
    Korkmaz, Selcuk
    Yazici, Ahmet Taylan
    Demirok, Ahmet
    CLINICAL OPHTHALMOLOGY, 2014, 8 : 685 - 690
12345